Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Clinical Cancer Research

• Publication date

  2003-11-01

• Fields of study

  Medicine

• Identifiers
  PMID 14613999
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-Small Cell Lung Cancer Cells

  2004cited by this paper
• Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.

  2002cited by this paper
• Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.

  2002cited by this paper
• Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG).

  2001cited by this paper
• E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo.

  2001cited by this paper

• Alternative splicing: from tumorigenesis to neoantigen-mediated cancer immunotherapy

  2025cites this paper
• Methylation of RBM39 by PRMT6 enhances resistance to Indisulam in non-small cell lung cancer by promoting alternative splicing of proto-oncogenes

  2025cites this paper
• Recent advances in anticancer mechanisms of molecular glue degraders: focus on RBM39-dgrading synthetic sulfonamide such as indisulam, E7820, tasisulam, and chloroquinoxaline sulfonamide

  2024cites this paper
• RNA splicing factors in normal hematopoiesis and hematologic malignancies: novel therapeutic targets and strategies.

  2023cites this paper
• Molecular Glue Degraders : From Serendipity to Hunting and Design

  2022cites this paper
• Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma

  2022cites this paper
• RNA-binding protein 39: a promising therapeutic target for cancer

  2021cites this paper
• Use of pH-interfering agents as chemosensitizers: Clinical studies survey

  2021cites this paper
• Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity

  2021cites this paper
• RNA-binding protein 39: a promising therapeutic target for cancer

  2021cites this paper
• Therapeutic approaches targeting splicing factor mutations in myelodysplastic syndromes and acute myeloid leukemia

  2021cites this paper
• Genetic and compound screens uncover factors modulating cancer cell response to indisulam

  2021cites this paper
• RNA‐binding motif protein 39 (RBM39): An emerging cancer target

  2020cites this paper
• Targeting the E3 Ubiquitin Ligases DCAF15 and Cereblon for Cancer Therapy.

  2020cites this paper
• pSILAC method coupled with two complementary digestion approaches reveals PRPF39 as a new E7070-dependent DCAF15 substrate.

  2020cites this paper
• Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies

  2019cites this paper
• Aberrant RNA Splicing in Cancer.

  2019cites this paper
• Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15

  2017cites this paper
• Small molecule mediated targeting of haematopoietic stem/progenitor cell and leukaemic stem cell function

  2017cites this paper
• Therapeutic targeting of RNA splicing in myelodysplasia.

  2017cites this paper
• Palbociclib: A breakthrough in breast carcinoma in women.

  2016cites this paper
• Iridium(III)-Catalyzed Regioselective C7-Amination of N-Pivaloylindoles with Sulfonoazides.

  2016cites this paper
• Manipulating the Tumor Microenvironment for Therapeutic Benefit

  2014cites this paper
• Potential biofluid markers and treatment targets for renal cell carcinoma

  2013cites this paper
• Discovery of Novel 2‐N‐Aryl‐Substituted Benzenesulfonamidoacetamides: Orally Bioavailable Tubulin Polymerization Inhibitors with Marked Antitumor Activities

  2012cites this paper
• Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment

  2012cites this paper
• A novel sulfonamide agent, MPSP-001, exhibits potent activity against human cancer cells in vitro through disruption of microtubule

  2012cites this paper
• Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

  2011cites this paper
• Novel, selective CDK9 inhibitors for the treatment of HIV infection.

  2011cites this paper
• Synthesis and anticancer activities of new Benzothiadiazinyl Hydrazinecarboxamides and Anilino[1,2,4]triazolo[1,5-b][1,2,4]thiadiazine 5,5-diones.

  2011cites this paper
• Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

  2011cites this paper
• Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies

  2010cites this paper
• Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents

  2009cites this paper
• Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression

  2009cites this paper
• PK/PD Model of Indisulam and Capecitabine: Interaction Causes Excessive Myelosuppression

  2008cites this paper
• CDK Inhibitors as Anticancer Agents

  2008cites this paper
• Drugs That Inhibit Signalling Pathways for Tumor Cell Growth and Proliferation

  2008cites this paper
• A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours

  2008cites this paper
• A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer

  2007cites this paper
• Rational Drug Design of Small Molecule Anticancer Agents: Early Clinical Development

  2007cites this paper
• Targeting cell cycle kinases and kinesins in anticancer drug development

  2007influential citation
• Clinical complete long-term remission of a patient with metastatic malignant melanoma under therapy with indisulam (E7070).

  2007cites this paper
• CYP2C9 and CYP2C19 Polymorphic Forms Are Related to Increased Indisulam Exposure and Higher Risk of Severe Hematologic Toxicity

  2007cites this paper
• Cyclin-Dependent Kinase Inhibitors and Combination Therapy: Experimental and Clinical Status

  2006cites this paper
• SATURABLE BINDING OF INDISULAM TO PLASMA PROTEINS AND DISTRIBUTION TO HUMAN ERYTHROCYTES

  2006cites this paper
• Cyclin-dependent kinases as targets for cancer therapy.

  2006cites this paper
• CDK inhibitors in 3D: Problems with the drugs, their development plans or their linkage to disease?

  2006cites this paper
• A Semi-Physiological Population Pharmacokinetic Model Describing the Non-linear Disposition of Indisulam

  2006cites this paper
• Interactions between hypoxia and epidermal growth factor receptor in non-small-cell lung cancer.

  2006cites this paper
• Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam

  2005cites this paper
• Phase II study of E7070 in patients with metastatic melanoma.

  2005cites this paper
• Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days

  2005cites this paper
• Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors.

  2005cites this paper
• Review: potential role of cell cycle synchronizing agents in combination treatment modalities of malignant tumors.

  2005cites this paper
• Phase II study of E 7070 in patients with metastatic melanoma

  2004cites this paper
• Gateways to clinical trials.

  2004cites this paper
• Novel arylsulfoanilide-oxindole hybrid as an anticancer agent that inhibits translation initiation.

  2004cites this paper
• A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck

  2004cites this paper
• Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).

  2002cites this paper